Boehringer 1218
This study will assess how well empagliflozin and linagliptin work in children and adolescents.

Type of Study:
Type 2 diabetes patients who are between 10 to 17 years

Study Length:
52 weeks

Target Age/Sex:
10 – 17 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Closed

Description:

This study will assess how well empagliflozin and linagliptin work in children and adolescents(DINAMO).

This Study is Closed.